Announcing a new publication for Acta Materia Medica journal. Alzheimer’s disease (AD), an irreversible neurodegenerative disease that progressively impairs memory and cognitive judgment, severely affects the quality of life and imposes a heavy burden on the healthcare system. No cure is currently available for AD, in part because the pathogenesis of this disease has not […]
Tag: Alzheimer’s disease
Acta Materia Medica Call for Papers
Acta Materia Medica provides an open platform for rapid publication of the latest findings, approaches, and viewpoints related to all related areas of pharmacy and pharmaceutical sciences, including, but are not limited to, pharmacology, toxicology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis, pharmacokinetics, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics and pharmacy management. Article types accepted: Research […]
Regulation of Neuronal Autophagy and Cell Survival by MCL1 in Alzheimer’s Disease
Announcing a new review article publication for Acta Materia Medica journal. In this review article, the authors discuss the emerging neuroprotective function of MCL1 and how dysregulation of MCL1 signaling is involved in the pathogenesis of AD. Because members of the pro-survival BCL2 family proteins are promising targets of pharmacological intervention with BH3 mimetic drugs, […]
PROTAC Technology for the Treatment of Alzheimer’s Disease: Advances and Perspectives
Announcing a new review article publication for Acta Materia Medica journal. Although PROTAC technology is preferable to oligonucleotides and antibodies for the treatment of neurodegenerative diseases, many limitations, such as their pharmacokinetic properties, tissue distribution, and cell permeability, must be addressed. The authors of this article review recent advances in PROTAC technology, as well as […]